Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 174 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Wet AMD Clear all
Completed Phase 4 Interventional Results available

The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy

NCT03022292
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Aflibercept Ophthalmic, optovue angiovue
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 30, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD

NCT02214628
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Fovista® (anti-PDGF BB) plus anti-VEGF
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
13
States / cities
Phoenix, Arizona • Beverly Hills, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 30, 2026, 10:58 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Small Interfering Ribonucleic Acid (RNA) Molecule (Cand5) to Treat Wet Age-Related Macular Degeneration

NCT00259753
View directory record Official record
Conditions
Macular Degeneration
Interventions
Bevasiranib
Drug
Lead sponsor
OPKO Health, Inc.
Industry
Eligibility
50 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Artesia, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2008 · Synced Oct 30, 2026, 10:58 AM EDT
Completed Phase 4 Interventional

Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)

NCT01863199
View directory record Official record
Conditions
Neovascular Age Related Macular Degeneration
Interventions
Lucentis (Treat and extend), Lucentis every 4 weeks, Lucentis every 12 weeks
Drug
Lead sponsor
Retinal Consultants of Arizona
Other
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
4
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 30, 2026, 10:58 AM EDT
Completed No phase listed Observational

Triple Combination Therapy of Choroidal Neovascularization in AMD, a Cost Effect and Efficient Therapeutic Treatment

NCT02287298
View directory record Official record
Conditions
Exudative Macular Degeneration
Interventions
TRIPLE COMBINATION THERAPY
Procedure
Lead sponsor
The Retina Center of St. Louis County, PC
Other
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 30, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

MMP-9 Inhibition for Recalcitrant Wet AMD

NCT04504123
View directory record Official record
Conditions
Exudative Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
Doxycycline Hyclate, Placebo
Drug
Lead sponsor
University of Iowa
Other
Eligibility
50 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 30, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional

TAC-PF, Avastin® in Combination With Photodynamic Therapy to Treat Age Related Macular Degeneration

NCT00464347
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Avastin, Photodynamic Therapy (PDT), Preservative-Free Triamcinolone Acetonide (TAC-PF)
Drug · Procedure
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
11
States / cities
Fort Lauderdale, Florida • Orlando, Florida • Pensacola, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 30, 2026, 10:58 AM EDT
Active, not recruiting Phase 3 Interventional

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56

NCT06683742
View directory record Official record
Conditions
Wet Age Related Macular Degeneration, wAMD
Interventions
EYP-1901, Aflibercept (2.0 mg)
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
50 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
78
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 10:58 AM EDT
Completed Phase 1Phase 2 Interventional

Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration

NCT02140151
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Southern California Desert Retina Consultants, MC
Other
Eligibility
50 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
Mountain View, California • Palm Desert, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Oct 30, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

NCT03869684
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
MT-0814, Placebo
Drug
Lead sponsor
Senju Pharmaceutical Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
13
States / cities
Peoria, Arizona • Phoenix, Arizona • Pasadena, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 30, 2026, 10:58 AM EDT
Not listed Not applicable Interventional

Supplemental Adjuvants for Intracellular Nutrition and Treatment

NCT00893724
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
Neutral pills with no medicinal effect, Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals, Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
Drug · Dietary Supplement
Lead sponsor
Mid-Atlantic Retina Consultations, Inc.
Other
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Oct 30, 2026, 10:58 AM EDT
Terminated Phase 2 Interventional

MSI-1256F (Squalamine Lactate) in Combination With Verteporfin in Patients With "Wet" Age-Related Macular Degeneration (AMD)

NCT00094120
View directory record Official record
Conditions
Macular Degeneration
Interventions
MSI-1256F (Squalamine Lactate)
Drug
Lead sponsor
Genaera Corporation
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Plymouth Meeting, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2008 · Synced Oct 30, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

ADVM-022 Intravitreal Gene Therapy for Wet AMD

NCT03748784
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
11
States / cities
Bakersfield, California • Beverly Hills, California • Golden, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 30, 2026, 10:58 AM EDT
Terminated Phase 1 Interventional

Study of Talaporfin Sodium Photodynamic Therapy to Treat Advanced Age Related Macular Disease

NCT00102115
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
Drug
Lead sponsor
Light Sciences LLC
Industry
Eligibility
50 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2010 · Synced Oct 30, 2026, 10:58 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

NCT02228304
View directory record Official record
Conditions
Macular Degeneration
Interventions
NT-503-3 ECT implantation, Eylea® injected intravitreally administered every 8 weeks
Drug
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Phoenix, Arizona • Beverly Hills, California • Irvine, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 30, 2026, 10:58 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Study of NT-101 Topical in Patients With Wet AMD

NCT07811726
View directory record Official record
Conditions
Wet Age Related Macular Degeneration
Interventions
NT-101 ophthalmic solution, Placebo
Drug
Lead sponsor
NexThera Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Bonita Springs, Florida • Tulsa, Oklahoma • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 10:58 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

NCT03834753
View directory record Official record
Conditions
Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
bevacizumab, ranibizumab
Biological
Lead sponsor
Outlook Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
50
States / cities
Tucson, Arizona • Arcadia, California • Beverly Hills, California + 46 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 30, 2026, 10:58 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324

NCT07484074
View directory record Official record
Conditions
Diabetic Macular Edema (DME), Neovascular (Wet) Age-Related Macular Degeneration
Interventions
Faricimab, OLN324
Drug
Lead sponsor
Ollin Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
29
States / cities
Phoenix, Arizona • Glendale, California • Pasadena, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 30, 2026, 10:58 AM EDT
Completed Phase 3 Interventional

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

NCT00058994
View directory record Official record
Conditions
Macular Degeneration, Maculopathy, Age-Related
Interventions
anecortave acetate
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2012 · Synced Oct 30, 2026, 10:58 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD)

NCT00775411
View directory record Official record
Conditions
Choroidal Neovascularization, Age-Related Maculopathy
Interventions
dexamethasone, ranibizumab
Drug · Biological
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 30, 2026, 10:58 AM EDT
Active, not recruiting No phase listed Observational

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

NCT04645212
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
9
States / cities
Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 30, 2026, 10:58 AM EDT
Not listed Phase 3 Interventional

A Study of Strontium90 Beta Radiation With Lucentis to Treat Age-Related Macular Degeneration

NCT00454389
View directory record Official record
Conditions
Macular Degeneration
Interventions
Epi-Rad90™ Ophthalmic System, ranibizumab
Device · Drug
Lead sponsor
NeoVista
Industry
Eligibility
50 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 30, 2026, 10:58 AM EDT
Completed Phase 1Phase 2 Interventional

Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD

NCT03479372
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
PAN-90806 Ophthalmic Suspension
Drug
Lead sponsor
PanOptica, Inc.
Industry
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Golden, Colorado • Hagerstown, Maryland • Henderson, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2019 · Synced Oct 30, 2026, 10:58 AM EDT
Recruiting Phase 1Phase 2 Interventional

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

NCT05197270
View directory record Official record
Conditions
Neovascular (Wet) Age-Related Macular Degeneration
Interventions
4D-150 IVT, Aflibercept IVT
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
25
States / cities
Phoenix, Arizona • Oxnard, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 10:58 AM EDT